Abstract 613P
Background
Physicians have frequent interactions with the pharmaceutical industry (pharma), however, there is concern for possible corporate influence on physicians’ prescribing behaviours. We sought to understand perceptions and interactions between pharma and medical oncologists (MO), in comparison with infectious diseases (ID) physicians.
Methods
We conducted an anonymous online cross-sectional survey of Australian MO and ID physicians comparing self-reported interactions and attitudes with pharma. An additional survey was undertaken at Tan Tock Seng Hospital, Singapore.
Results
A total of 204 Australian and Singaporean physicians were surveyed including 102 oncologists and 102 ID physicians. Demographics including age, gender and years of practice between the two Australian specialties were similar, with an exception that most ID physicians had mainly public work (95% vs. 78% for oncologists, p<0.001). Oncologists had more frequent contact with pharma, the majority (69%) negotiating compassionate access for patients on a monthly/annual basis, compared with ID physicians who had never done so (45%), p<0.001. More ID physicians had never attended a sponsored meeting (15% ID vs. 27% MO respectively, p=0.01) or received travel/accommodation grants from pharma (42% ID vs. 85% MO respectively, p<0.001). However, most physicians (92%) had never received gifts from pharma, with no difference between groups (p=0.17). Most Australian oncologists believed that interacting with pharma was overall beneficial for patient care (78%) compared to ID physicians (34%, p<0.001). This statement was shared by 71% of Singaporean oncologists. Similar rates of Australian oncologists and ID physicians (83% vs. 88%, respectively) felt comfortable for patients to know the details of their interactions with pharma, however, only 57% of Singaporean oncologists agreed with this statement. Most Australian respondents (77%) agreed that there was strong public skepticism of these interactions (p=0.35).
Conclusions
Medical oncologists had more interactions with pharma than ID physicians and were more likely to believe that this was overall beneficial to patient care despite the negative public perception associated with this.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
P.L. Chia: Financial Interests, Personal, Advisory Board: Merck, Roche, Pfizer, Amgen; Financial Interests, Institutional, Research Funding: Merck, Roche, Pfizer, Amgen. T. John: Financial Interests, Personal, Invited Speaker, Speaker tour Vietnam: AstraZeneca; Financial Interests, Personal, Invited Speaker, CTIO: Merck Sharp Dohme; Financial Interests, Personal, Advisory Board: BMS, AstraZeneca, Bayer, Specialised Therapeutics; Financial Interests, Institutional, Advisory Board: Roche, Novartis, Pfizer, Amgen, Takeda, PharmaMar; Financial Interests, Personal, Other, Speaker/Chair: ACE Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract
321P - Epidemiology and survival analysis of epithelial ovarian cancer: Results from comprehensive care center in north India
Presenter: Amit Badola
Session: Poster Display
Resources:
Abstract
322P - Evaluation of chemotherapy response score as a prognostic factor in advanced epithelial ovarian cancer: A prospective single centre study
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
323P - Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio as prognostic biomarkers in ovarian cancer among the Asian population: A meta-analysis
Presenter: Wikania Wira Wiguna I Gede
Session: Poster Display
Resources:
Abstract
324P - All-<italic>trans</italic> retinoic acid sensitizes ovarian cancer to niraparib by inhibiting ALDH1A1 activity
Presenter: Bingjie Mei
Session: Poster Display
Resources:
Abstract
325TiP - A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)
Presenter: Myong Cheol Lim
Session: Poster Display
Resources:
Abstract
327TiP - A single arm phase II study of single agent pemetrexed in platinum resistant/refractory epithelial ovarian or primary peritoneal cancer
Presenter: Swasthik Parampalli
Session: Poster Display
Resources:
Abstract
337P - Demographic patterns and survival outcomes of patients with T and NK-cell lymphoma at the National Cancer Centre Singapore
Presenter: Mohamed Haniffa Bin Hasan Mohamed
Session: Poster Display
Resources:
Abstract
338P - Multicenter real-world study of advanced-stage non-nasal type NK/T cell lymphoma (NKTCL): Clinical features, treatment and prognosis
Presenter: Yuce Wei
Session: Poster Display
Resources:
Abstract
339P - A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy
Presenter: Kenta Hayashino
Session: Poster Display
Resources:
Abstract